Close

Vanda Pharmaceuticals (VNDA) Reports In-Line Q1 EPS, Revenues Miss

May 5, 2021 4:13 PM EDT

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $62.67 million versus the consensus estimate of $68.5 million.

"Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZĀ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "In our clinical programs, we have made significant progress, reaching 85% randomization in our Phase III tradipitant study in gastroparesis and initiating a new clinical program for HETLIOZĀ® in delayed sleep phase disorder."

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings